Eric Rowinsky

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Lin Chia-Chi; Beeram Muralidhar; Rowinsky Eric K; Takimoto Chris H; Ng Chee M; Geyer Charles E; Denis Louis J; De Bono Johann S; Hao Desiree; Tolcher Anthony W; Rha Sun-Young; Jolivet Jacques; Patnaik Amita
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
Mita Monica; Mita Alain; Sarantopoulos John; Takimoto Chris H; Rowinsky Eric K; Romero Ofelia; Angiuli Patrizia; Allievi Cecilia; Eisenfeld Amy; Verschraegen Claire F
Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.
Goel Sanjay; Mita Alain C; Mita Monica; Rowinsky Eric K; Chu Quincy S; Wong Nancy; Desjardins Christopher; Fang Fang; Jansen Mendel; Shuster Dale E; Mani Sridhar; Takimoto Chris H
A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Eric Rowinsky (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Lin Chia-Chi; Beeram Muralidhar; Rowinsky Eric K; Takimoto Chris H; Ng Chee M; Geyer Charles E; Denis Louis J; De Bono Johann S; Hao Desiree; Tolcher Anthony W; Rha Sun-Young; Jolivet Jacques; Patnaik Amita
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
Cancer chemotherapy and pharmacology 2009;65(1):167-75.
2009: Mita Monica; Mita Alain; Sarantopoulos John; Takimoto Chris H; Rowinsky Eric K; Romero Ofelia; Angiuli Patrizia; Allievi Cecilia; Eisenfeld Amy; Verschraegen Claire F
Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.
Cancer chemotherapy and pharmacology 2009;64(2):287-95.
2009: Goel Sanjay; Mita Alain C; Mita Monica; Rowinsky Eric K; Chu Quincy S; Wong Nancy; Desjardins Christopher; Fang Fang; Jansen Mendel; Shuster Dale E; Mani Sridhar; Takimoto Chris H
A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(12):4207-12.
2009: Forouzesh Bahram; Hidalgo Manuel; Chu Quincy; Mita Alain; Mita Monica; Schwartz Garry; Jimeno José; Gómez Javier; Alfaro Vicente; Lebedinsky Claudia; Zintl Patrik; Rowinsky Eric K
Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(10):3591-9.
2009: Lockhart A Craig; Calvo Emiliano; Tolcher Anthony W; Rowinsky Eric K; Shackleton Gareth; Morrison J Gilmour; Rafi Rezvan; VerMeulen Wendy; Rothenberg Mace L
A phase I dose-escalation study of SR271425, an intravenously dosed thioxanthone analog, administered weekly in patients with refractory solid tumors.
American journal of clinical oncology 2009;32(1):9-14.
2009: Mita Alain C; Denis Louis J; Rowinsky Eric K; Debono Johann S; Goetz Andrew D; Ochoa Leonel; Forouzesh Bahram; Beeram Muralidhar; Patnaik Amita; Molpus Kathleen; Semiond Dorothée; Besenval Michèle; Tolcher Anthony W
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(2):723-30.
2008: Ricart Alejandro D; Berlin Jordan D; Papadopoulos Kyriakos P; Syed Samira; Drolet Daniel W; Quaratino-Baker Charlotte; Horan Julie; Chick Jon; Vermeulen Wendy; Tolcher Anthony W; Rowinsky Eric K; Rothenberg Mace L
Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(23):7947-55.
2008: Lurje Georg; Nagashima Fumio; Zhang Wu; Yang Dongyun; Chang Heung M; Gordon Michael A; El-Khoueiry Anthony; Husain Hatim; Wilson Peter M; Ladner Robert D; Mauro David J; Langer Christiane; Rowinsky Eric K; Lenz Heinz-Josef
Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(23):7884-95.
2008: Baker Laurence H; Rowinsky Eric K; Mendelson David; Humerickhouse Rod A; Knight Raymond A; Qian Jiang; Carr Robert A; Gordon Gary B; Demetri George D
Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(34):5583-8.
2008: de Bono Johann S; Kristeleit Rebecca; Tolcher Anthony; Fong Peter; Pacey Simon; Karavasilis Vasilios; Mita Monica; Shaw Heather; Workman Paul; Kaye Stan; Rowinsky Eric K; Aherne Wynne; Atadja Peter; Scott Jeffrey W; Patnaik Amita
Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(20):6663-73.
2008: Chu Quincy S C; Cianfrocca Mary E; Goldstein Lori J; Gale Meg; Murray Nicholas; Loftiss Jill; Arya Nikita; Koch Kevin M; Pandite Lini; Fleming Ronald A; Paul Elaine; Rowinsky Eric K
A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(14):4484-90.
2008: Mita Monica M; Mita Alain C; Chu Quincy S; Rowinsky Eric K; Fetterly Gerald J; Goldston Michelle; Patnaik Amita; Mathews Lesley; Ricart Alejandro D; Mays Theresa; Knowles Heather; Rivera Victor M; Kreisberg Jeff; Bedrosian Camille L; Tolcher Anthony W
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(3):361-7.
2007: Sparreboom Alex; Wolff Antonio C; Mathijssen Ron H J; Chatelut Etienne; Rowinsky Eric K; Verweij Jaap; Baker Sharyn D
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(30):4707-13.
2007: Rowinsky Eric K; Youssoufian Hagop; Tonra James R; Solomon Phillip; Burtrum Douglas; Ludwig Dale L
IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(18 Pt 2):5549s-5555s.
2007: Youssoufian Hagop; Hicklin Daniel J; Rowinsky Eric K
Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(18 Pt 2):5544s-5548s.
2007: Chu Quincy S C; Schwartz Garry; de Bono Johann; Smith Deborah A; Koch Kevin M; Versola Melissa J; Pandite Lini; Arya Nikita; Curtright Jan; Fleming Ronald A; Ho Peter T C; Rowinsky Eric K
Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(24):3753-8.
2007: Chu Quincy S C; Forouzesh Bahram; Syed Samira; Mita Monica; Schwartz Garry; Cooper Joshua; Curtright Janet; Rowinsky Eric K
A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas.
Investigational new drugs 2007;25(4):359-67.
2007: Dragovich Tomislav; Huberman Mark; Von Hoff Daniel D; Rowinsky Eric K; Nadler Paul; Wood Debra; Hamilton Marta; Hage George; Wolf Julie; Patnaik Amita
Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.
Cancer chemotherapy and pharmacology 2007;60(2):295-303.
2007: Mita Alain C; Olszanski Anthony J; Walovitch Richard C; Perez Raymond P; MacKay Kathleen; Tuck David P; Simmons Cecilia; Hammond Susan; Mita Monica M; Beeram Muralidhar; Stone Anne J; Rowinsky Eric K; Lewis Lionel D
Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(11):3293-301.
2007: Curran Desmond; Giralt Jordi; Harari Paul M; Ang K Kian; Cohen Roger B; Kies Merrill S; Jassem Jacek; Baselga José; Rowinsky Eric K; Amellal Nadia; Comte Sylvie; Bonner James A
Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(16):2191-7.
2007: Takimoto Chris H; Hammond-Thelin Lisa A; Latz Jane E; Forero Leonardo; Beeram Muralidhar; Forouzesh Bahram; de Bono Johann; Tolcher Anthony W; Patnaik Amita; Monroe Pamela; Wood Leslie; Schneck Karen B; Clark Romnee; Rowinsky Eric K
Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(9):2675-83.
2007: Youssoufian Hagop; Rowinsky Eric K
A remedy for biomarker addiction: back to rational anticancer drug development.
Nature clinical practice. Oncology 2007;4(5):264-5.
2007: Calvo E; Malik S N; Siu L L; Baillargeon G M; Irish J; Chin S F; Santabarbara P; Kreisberg J I; Rowinsky E K; Hidalgo M
Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(4):761-7.
2007: Mita Monica M; Rowinsky Eric K; Forero Leonardo; Eckhart S Gail; Izbicka Elzbieta; Weiss Geoffrey R; Beeram Muralidhar; Mita Alain C; de Bono Johann S; Tolcher Anthony W; Hammond Lisa A; Simmons Paul; Berg Kristin; Takimoto Chris; Patnaik Amita
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Cancer chemotherapy and pharmacology 2007;59(2):165-74.
2007: Rowinsky Eric K; Beeram Muralidhar; Hammond Lisa A; Schwartz Garry; De Bono Johann; Forouzesh Baharam; Chu Quincy; Latz Jane E; Hong Shengyan; John William; Nguyen Binh
A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(2 Pt 1):532-9.
2006: Patnaik Amita; Wood Debra; Tolcher Anthony W; Hamilton Marta; Kreisberg Jeffrey I; Hammond Lisa A; Schwartz Garry; Beeram Muralidhar; Hidalgo Manuel; Mita Monica M; Wolf Julie; Nadler Paul; Rowinsky Eric K
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(24):7406-13.
2006: Lenz Heinz-Josef; Van Cutsem Eric; Khambata-Ford Shirin; Mayer Robert J; Gold Philip; Stella Philip; Mirtsching Barry; Cohn Allen L; Pippas Andrew W; Azarnia Nozar; Tsuchihashi Zenta; Mauro David J; Rowinsky Eric K
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(30):4914-21.
2006: Hidalgo Manuel; Buckner Jan C; Erlichman Charles; Pollack Marilyn S; Boni Joseph P; Dukart Gary; Marshall Bonnie; Speicher Lisa; Moore Laurence; Rowinsky Eric K
A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(19):5755-63.
2006: Mita Alain C; Hammond Lisa A; Bonate Peter L; Weiss Geoffrey; McCreery Heather; Syed Samira; Garrison Mitchell; Chu Quincy S C; DeBono Johann S; Jones Christopher B; Weitman Steve; Rowinsky Eric K
Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(17):5207-15.
2006: Rowinsky Eric K; Calvo Emiliano
Novel agents that target tublin and related elements.
Seminars in oncology 2006;33(4):421-35.
2006: Rowinsky Eric K
Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(19):2981-4.
2006: Ratain Mark J; Eisen Tim; Stadler Walter M; Flaherty Keith T; Kaye Stan B; Rosner Gary L; Gore Martin; Desai Apurva A; Patnaik Amita; Xiong Henry Q; Rowinsky Eric; Abbruzzese James L; Xia Chenghua; Simantov Ronit; Schwartz Brian; O'Dwyer Peter J
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(16):2505-12.
2006: Erlichman Charles; Hidalgo Manuel; Boni Joseph P; Martins Patricia; Quinn Susan E; Zacharchuk Charles; Amorusi Peter; Adjei Alex A; Rowinsky Eric K
Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(15):2252-60.
2006: Tolcher Anthony W; Hao Desiree; de Bono Johann; Miller Alex; Patnaik Amita; Hammond Lisa A; Smetzer Leslie; Van Wart Hood Jill; Merritt James; Rowinsky Eric K; Takimoto Chris; Von Hoff Dan; Eckhardt S Gail
Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(13):2052-8.
2006: Lee Carlton K K; Rowinsky Eric K; Li Jing; Giles Francis; Moore Malcolm J; Hidalgo Manuel; Capparelli Edmund; Jolivet Jacques; Baker Sharyn D
Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):2158-65.
2006: Bonner James A; Harari Paul M; Giralt Jordi; Azarnia Nozar; Shin Dong M; Cohen Roger B; Jones Christopher U; Sur Ranjan; Raben David; Jassem Jacek; Ove Roger; Kies Merrill S; Baselga Jose; Youssoufian Hagop; Amellal Nadia; Rowinsky Eric K; Ang K Kian
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
The New England journal of medicine 2006;354(6):567-78.
2006: Mita Alain C; Sweeney Christopher J; Baker Sharyn D; Goetz Andrew; Hammond Lisa A; Patnaik Amita; Tolcher Anthony W; Villalona-Calero Miguel; Sandler Alan; Chaudhuri Tuhin; Molpus Kathleen; Latz Jane E; Simms Lorinda; Chaudhary Ajai K; Johnson Robert D; Rowinsky Eric K; Takimoto Chris H
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(4):552-62.
2006: Mita M M; Ochoa L; Rowinsky E K; Kuhn J; Schwartz G; Hammond L A; Patnaik A; Yeh I-T; Izbicka E; Berg K; Tolcher A W
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(2):313-21.
2006: Sweeney Christopher J; Takimoto Chris H; Latz Jane E; Baker Sharyn D; Murry Daryl J; Krull James H; Fife Karen; Battiato Linda; Cleverly Ann; Chaudhary Ajai K; Chaudhuri Tuhin; Sandler Alan; Mita Alain C; Rowinsky Eric K
Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(2):536-42.
2005: Rowinsky Eric K
Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(36):9394-407.
2005: Ricart Alejandro D; Hammond Lisa A; Kuhn John G; Takimoto Chris H; Goetz Andrew; Forouzesh Bahram; Forero Leonardo; Ochoa-Bayona Jose L; Berg Kristin; Tolcher Anthony W; Rowinsky Eric K
Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(24 Pt 1):8728-36.
2005: Posey James A; Saif M Wasif; Carlisle Ronda; Goetz Andrew; Rizzo Jinee; Stevenson Suzanne; Rudoltz Marc S; Kwiatek Joseph; Simmons Paul; Rowinsky Eric K; Takimoto Chris H; Tolcher Anthony W
Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(21):7866-71.
2005: Rowinsky Eric K
Erosion of the principal investigator role in a climate of industry dominance.
European journal of cancer (Oxford, England : 1990) 2005;41(15):2206-9.
2005: Beeram Muralidhar; Patnaik Amita; Rowinsky Eric K
Raf: a strategic target for therapeutic development against cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(27):6771-90.
2005: Abou-Alfa Ghassan K; Rowinsky Eric K; Patt Yehuda Z; Schwartz Gary K; Kelsen David P; Sharma Sunil; Siegel Eve; Becerra Carlos R; Eckhardt S Gail; Feit Kevie; De Jager Robert; O'Reilly Eileen M
A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers.
American journal of clinical oncology 2005;28(4):334-9.
2005: Tolcher Anthony W; Chi Kim; Kuhn John; Gleave Martin; Patnaik Amita; Takimoto Chris; Schwartz Garry; Thompson Ian; Berg Kristin; D'Aloisio Susan; Murray Nevin; Frankel Stanley R; Izbicka Elzbieta; Rowinsky Eric
A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(10):3854-61.
2005: Calvo Emiliano; Rowinsky Eric K
Approaches to optimize the use of monoclonal antibodies to epidermal growth factor receptor.
Current oncology reports 2005;7(2):123-8.
2005: Calvo Emiliano; Rowinsky Eric K
Clinical experience with monoclonal antibodies to epidermal growth factor receptor.
Current oncology reports 2005;7(2):96-103.
2004: Calvo Emiliano; Rowinsky Eric K
Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based drugs.
Clinical lung cancer 2004;6 Suppl 1():S35-42.
2004: de Bono J S; Rha S Y; Stephenson J; Schultes B C; Monroe P; Eckhardt G S; Hammond L A; Whiteside T L; Nicodemus C F; Cermak J M; Rowinsky E K; Tolcher A W
Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(12):1825-33.
2004: Rowinsky Eric K
Targeting the molecular target of rapamycin (mTOR).
Current opinion in oncology 2004;16(6):564-75.
2004: de Bono Johann S; Tolcher Anthony W; Forero Andre; Vanhove Gertrude F A; Takimoto Chris; Bauer Robert J; Hammond Lisa A; Patnaik Amita; White Mark L; Shen Sui; Khazaeli Muhammad B; Rowinsky Eric K; LoBuglio Albert F
ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(22):7555-65.
2004: Calvo Emiliano; Tolcher Anthony W; Hammond Lisa A; Patnaik Amita; de Bono Johan S; Eiseman Irene A; Olson Stephen C; Lenehan Peter F; McCreery Heather; Lorusso Patricia; Rowinsky Eric K
Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(21):7112-20.
2004: Schwartz Garry H; Jones Christopher B; Garrison Mitchell; Patnaik Amita; Takimoto Chris; McCreery Heather; Skinner Michael; Tolcher Anthony W; Rowinsky Eric K
A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.
Investigational new drugs 2004;22(4):437-48.
2004: Rowinsky Eric
New antimitotic agents.
Clinical advances in hematology & oncology : H&O 2004;2(10):636-7.
2004: Syed Samira; Takimoto Chris; Hidalgo Manuel; Rizzo Jinee; Kuhn John G; Hammond Lisa A; Schwartz Garry; Tolcher Anthony; Patnaik Amita; Eckhardt S Gail; Rowinsky Eric K
A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(19):6512-21.
2004: Pérez-Soler Román; Chachoua Abraham; Hammond Lisa A; Rowinsky Eric K; Huberman Mark; Karp Daniel; Rigas James; Clark Gary M; Santabárbara Pedro; Bonomi Philip
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(16):3238-47.
2004: Tolcher Anthony W; Kuhn John; Schwartz Garry; Patnaik Amita; Hammond Lisa A; Thompson Ian; Fingert Howard; Bushnell David; Malik Shazli; Kreisberg Jeffrey; Izbicka Elzbieta; Smetzer Leslie; Rowinsky Eric K
A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(15):5048-57.
2004: Chu Quincy Siu-Chung; Hammond Lisa A; Schwartz Garry; Ochoa Leonel; Rha Sun-Young; Denis Louis; Molpus Kathleen; Roedig Brian; Letrent Stephen P; Damle Bharat; DeCillis Arthur P; Rowinsky Eric K
Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(15):4913-21.
2004: Rowinsky Eric K; Schwartz Garry H; Gollob Jared A; Thompson John A; Vogelzang Nicholas J; Figlin Robert; Bukowski Ronald; Haas Naomi; Lockbaum Pamela; Li Yu-Ping; Arends Rosalin; Foon Kenneth A; Schwab Gisela; Dutcher Janice
Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(15):3003-15.
2004: Mita Alain C; Mita Monica M; Rowinsky Eric K
Development of rationally designed, target-based agents for the treatment of advanced colorectal cancer.
Clinical colorectal cancer 2004;4(2):107-23.
2004: Rowinsky Eric K
Curtailing the high rate of late-stage attrition of investigational therapeutics against unprecedented targets in patients with lung and other malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 2):4220s-4226s.
2004: Lynch Thomas J; Adjei Alex A; Bunn Paul A; DuBois Raymond N; Gandara David R; Giaccone Giuseppe; Govindan Ramaswamy; Herbst Roy S; Johnson Bruce E; Khuri Fadlo R; Perez-Soler Roman; Rosell Rafael; Rowinsky Eric K; Sandler Alan B; Scagliotti Giorgio V; Schiller Joan H; Shapiro Geoffrey I; Socinski Mark A; Hart Carol S
Novel agents in the treatment of lung cancer: conference summary statement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 2):4199s-4204s.
2004: Melendez Robert F; Harrison Joseph M; Rowinsky Eric K; Hammond Lisa A; Fitzsimmons Thomas D
Acute retinal toxicity from the novel anti-tumor agent, Irofulven.
Documenta ophthalmologica. Advances in ophthalmology 2004;108(3):249-51.
2004: Rowinsky Eric K
A widening prospect: Imatinib and novel applications of targeted therapy.
Seminars in oncology 2004;31(2 Suppl 6):1-3.
2004: Hammond Lisa A; Eckardt John R; Kuhn John G; Gerson Stanton L; Johnson Tom; Smith Lon; Drengler Ronald L; Campbell Elizabeth; Weiss Geoffrey R; Von Hoff Daniel D; Rowinsky Eric K
A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(5):1645-56.
2004: Foon Kenneth A; Yang Xiao-Dong; Weiner Louis M; Belldegrun Arie S; Figlin Robert A; Crawford Jeffrey; Rowinsky Eric K; Dutcher Janice P; Vogelzang Nicholas J; Gollub Jared; Thompson John A; Schwartz Garry; Bukowski Ronald M; Roskos Lorin K; Schwab Gisela M
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody.
International journal of radiation oncology, biology, physics 2004;58(3):984-90.
2004: Royce Melanie E; Rowinsky Eric K; Hoff Paulo M; Coyle John; DeJager Robert; Pazdur Richard; Saltz Leonard B
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum.
Investigational new drugs 2004;22(1):53-61.
2004: Rowinsky Eric K
The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors.
Annual review of medicine 2004;55():433-57.
2003: Forouzesh Bahram; Takimoto Chris H; Goetz Andrew; Diab Sami; Hammond Lisa A; Smetzer Leslie; Schwartz Garry; Gazak Robert; Callaghan John T; Von Hoff Daniel D; Rowinsky Eric K
A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(15):5540-9.
2003: de Bono Johann S; Tolcher Anthony W; Rowinsky Eric K
Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma.
Seminars in oncology 2003;30(5 Suppl 16):79-92.
2003: Syed Samira; Rowinsky Eric
The new generation of targeted therapies for breast cancer.
Oncology (Williston Park, N.Y.) 2003;17(10):1339-51; discussion 1352, 1355-6.
2003: Patnaik Amita; Eckhardt S Gail; Izbicka Elzbieta; Tolcher Anthony A; Hammond Lisa A; Takimoto Chris H; Schwartz Garry; McCreery Heather; Goetz Andrew; Mori Masataka; Terada Kazutoyo; Gentner Lou; Rybak Mary-Ellen; Richards Henry; Zhang Steven; Rowinsky Eric K
A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(13):4761-71.
2003: Beeram Muralidhar; Patnaik Amita; Rowinsky Erick K
Regulation of c-Raf-1: therapeutic implications.
Clinical advances in hematology & oncology : H&O 2003;1(8):476-81.
2003: O'Reilly Seamus; O'Hearn Elizabeth; Struck Robert F; Rowinsky Eric K; Molliver Mark E
The alkylating agent penclomedine induces degeneration of purkinje cells in the rat cerebellum.
Investigational new drugs 2003;21(3):269-79.
2003: Takimoto Chris H; Rowinsky Eric K
Dose-intense paclitaxel: deja vu all over again?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(15):2810-4.
2003: Mita Monica M; Mita Alain; Rowinsky Eric K
The molecular target of rapamycin (mTOR) as a therapeutic target against cancer.
Cancer biology & therapy 2003;2(4 Suppl 1):S169-77.
2003: Adjei Alex A; Rowinsky Eric K
Novel anticancer agents in clinical development.
Cancer biology & therapy 2003;2(4 Suppl 1):S5-15.
2003: Garrison Mitchell A; Hammond Lisa A; Geyer Charles E; Schwartz Garry; Tolcher Anthony W; Smetzer Leslie; Figueroa Jose A; Ducharme Murray; Coyle John; Takimoto Chris H; De Jager Robert L; Rowinsky Eric K
A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(7):2527-37.
2003: Malik Shazli N; Siu Lillian L; Rowinsky Eric K; deGraffenried Linda; Hammond Lisa A; Rizzo Jinee; Bacus Sarah; Brattain Michael G; Kreisberg Jeffrey I; Hidalgo Manuel
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(7):2478-86.
2003: Hao Desirée; Hammond Lisa A; Eckhardt S Gail; Patnaik Amita; Takimoto Chris H; Schwartz Garry H; Goetz Andrew D; Tolcher Anthony W; McCreery Heather A; Mamun Khalid; Williams Jon I; Holroyd Kenneth J; Rowinsky Eric K
A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(7):2465-71.
2003: Mita Monica M; Mita Alain; Rowinsky Eric K
Mammalian target of rapamycin: a new molecular target for breast cancer.
Clinical breast cancer 2003;4(2):126-37.
2003: Rowinsky Eric K
Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(10 Suppl):175s-186s.
2003: Cannistra Stephen A; Bast Robert C; Berek Jonathan S; Bookman Michael A; Crum Christopher P; DePriest Paul D; Garber Judy E; Koh Wui-Jin; Markman Maurie; McGuire William P; Rose Peter G; Rowinsky Eric K; Rustin Gordon J S; Skates Steven J; Vasey Paul A; King Laura
Progress in the management of gynecologic cancer: consensus summary statement.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(10 Suppl):129s-132s.
2003: Schwartz G H; Patnaik A; Hammond L A; Rizzo J; Berg K; Von Hoff D D; Rowinsky E K
A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(5):775-82.
2003: Meropol Neal J; Somer Robert A; Gutheil John; Pelley Robert J; Modiano Manuel R; Rowinsky Eric K; Rothenberg Mace L; Redding Spencer W; Serdar Cuneyt M; Yao Bin; Heard Robert; Rosen Lee S
Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(8):1452-8.
2003: Tolcher A W; Gerson S L; Denis L; Geyer C; Hammond L A; Patnaik A; Goetz A D; Schwartz G; Edwards T; Reyderman L; Statkevich P; Cutler D L; Rowinsky E K
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.
British journal of cancer 2003;88(7):1004-11.
2003: Dees E Claire; Rowinsky Eric K; Noe Dennis A; O'Reilly Seamus; Adjei Alex A; Elza-Brown Kathy; Donehower Ross C
A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancer.
Investigational new drugs 2003;21(1):75-84.
2003: Sledge George W; Neuberg Donna; Bernardo Patricia; Ingle James N; Martino Silvana; Rowinsky Eric K; Wood William C
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):588-92.
2003: Tolcher Anthony W; Ochoa Leonel; Hammond Lisa A; Patnaik Amita; Edwards Tam; Takimoto Chris; Smith Lon; de Bono Johann; Schwartz Garry; Mays Theresa; Jonak Zdenka L; Johnson Randall; DeWitte Mark; Martino Helen; Audette Charlene; Maes Kate; Chari Ravi V J; Lambert John M; Rowinsky Eric K
Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(2):211-22.
2003: Rowinsky Eric K; Rizzo Jinee; Ochoa Leonel; Takimoto Chris H; Forouzesh Bahram; Schwartz Garry; Hammond Lisa A; Patnaik Amita; Kwiatek Joseph; Goetz Andrew; Denis Louis; McGuire Jeffrey; Tolcher Anthony W
A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(1):148-57.
2003: Rowinsky Eric K
Signal events: Cell signal transduction and its inhibition in cancer.
The oncologist 2003;8 Suppl 3():5-17.
2003: Rowinsky Eric K
Crossing the cancer cell membrane to improve clinical outcomes.
The oncologist 2003;8 Suppl 3():1-4.
2003: de Bono Johann S; Tolcher Anthony W; Rowinsky Eric K
The future of cytotoxic therapy: selective cytotoxicity based on biology is the key.
Breast cancer research : BCR 2003;5(3):154-9.
2002: Baker Sharyn D; Verweij Jaap; Rowinsky Eric K; Donehower Ross C; Schellens Jan H M; Grochow Louise B; Sparreboom Alex
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.
Journal of the National Cancer Institute 2002;94(24):1883-8.
2002: Tolcher Anthony W; Takimoto Chris H; Rowinsky Eric K
The multifunctional, multi-institutional, and sometimes even global phase I study: a better life for phase I evaluations or just "living large"?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(21):4276-8.
2002: Rowinsky Eric K
Taxane analogues: distinguishing royal robes from the "Emperor's New Clothes".
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(9):2759-63.
2002: Lobell Robert B; Liu Dongming; Buser Carolyn A; Davide Joseph P; DePuy Elizabeth; Hamilton Kelly; Koblan Kenneth S; Lee Yih; Mosser Scott; Motzel Sherri L; Abbruzzese James L; Fuchs Charles S; Rowinsky Eric K; Rubin Eric H; Sharma Sunil; Deutsch Paul J; Mazina Kathryn E; Morrison Briggs W; Wildonger Lynne; Yao Siu-Long; Kohl Nancy E
Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I.
Molecular cancer therapeutics 2002;1(9):747-58.
2002: Siu Lillian L; Rowinsky Eric K; Hammond Lisa A; Weiss Geoffrey R; Hidalgo Manuel; Clark Gary M; Moczygemba Judy; Choi Les; Linnartz Ron; Barbet Nicholas C; Sklenar Ivo T; Capdeville Renaud; Gan Gregory; Porter Carl W; Von Hoff Daniel D; Eckhardt S Gail
A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2157-66.
2002: Patnaik Amita; Rowinsky Eric K; Villalona Miguel A; Hammond Lisa A; Britten Carolyn D; Siu Lillian L; Goetz Andrew; Felton Sally A; Burton Susan; Valone Frank H; Eckhardt S Gail
A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2142-8.
2002: Mould Diane R; Holford Nicholas H G; Schellens Jan H M; Beijnen Jos H; Hutson Paul R; Rosing Hilde; ten Bokkel Huinink Willem W; Rowinsky Eric K; Schiller Joan H; Russo Mark; Ross Graham
Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors.
Clinical pharmacology and therapeutics 2002;71(5):334-48.
2002: Ranson Malcolm; Hammond Lisa A; Ferry David; Kris Mark; Tullo Andrew; Murray Philip I; Miller Vince; Averbuch Steve; Ochs Judy; Morris Charles; Feyereislova Andrea; Swaisland Helen; Rowinsky Eric K
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(9):2240-50.
2002: Villalona-Calero Miguel A; Eckhardt S Gail; Weiss Geoffrey; Hidalgo Manuel; Beijnen Jos H; van Kesteren Charlotte; Rosing Hilde; Campbell Elizabeth; Kraynak Maura; Lopez-Lazaro Luis; Guzman Cecilia; Von Hoff Daniel D; Jimeno Jose; Rowinsky Eric K
A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(1):75-85.
2002: de Bono Johann S; Stephenson Joseph; Baker Sharyn D; Hidalgo Manuel; Patnaik Amita; Hammond Lisa A; Weiss Geoffrey; Goetz Andrew; Siu Lillian; Simmons Cecelia; Jolivet Jacques; Rowinsky Eric K
Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):96-109.
2002: de Bono Johann S; Rowinsky Eric K
Therapeutics targeting signal transduction for patients with colorectal carcinoma.
British medical bulletin 2002;64():227-54.
2002: Rowinsky Eric K
Weekly topotecan: an alternative to topotecan's standard daily x 5 schedule?
The oncologist 2002;7(4):324-30.
2002: Hao Desirée; Rowinsky Eric K
Inhibiting signal transduction: recent advances in the development of receptor tyrosine kinase and Ras inhibitors.
Cancer investigation 2002;20(3):387-404.
2002: de Bono Johann S; Rowinsky Eric K
The ErbB receptor family: a therapeutic target for cancer.
Trends in molecular medicine 2002;8(4 Suppl):S19-26.
2001: Britten C D; Rowinsky E K; Soignet S; Patnaik A; Yao S L; Deutsch P; Lee Y; Lobell R B; Mazina K E; McCreery H; Pezzuli S; Spriggs D
A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12):3894-903.
2001: O'Reilly S; Hartman N R; Bowling K M; Rowinsky E K; Donehower R C; Collins J; Strong J M
Bioavailability of penclomedine and systemic exposure to 4-O-demethylpenclomedine in patients receiving oral and intravenous penclomedine.
Cancer chemotherapy and pharmacology 2001;48(3):223-8.
2001: Gore S D; Weng L J; Zhai S; Figg W D; Donehower R C; Dover G J; Grever M; Griffin C A; Grochow L B; Rowinsky E K; Zabalena Y; Hawkins A L; Burks K; Miller C B
Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2330-9.
2001: Schwartz G; Johnson T R; Goetz A; Burris H; Smetzer L; Lampkin T; Sailstad J; Hohneker J A; Von Hoff D D; Rowinsky E K
A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(7):1901-11.
2001: Hidalgo M; Siu L L; Nemunaitis J; Rizzo J; Hammond L A; Takimoto C; Eckhardt S G; Tolcher A; Britten C D; Denis L; Ferrante K; Von Hoff D D; Silberman S; Rowinsky E K
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(13):3267-79.
2001: Tolcher A W; Eckhardt S G; Kuhn J; Hammond L; Weiss G; Rizzo J; Aylesworth C; Hidalgo M; Patnaik A; Schwartz G; Felton S; Campbell E; Rowinsky E K
Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(11):2937-47.
2001: Villalona-Calero M A; Blum J L; Jones S E; Diab S; Elledge R; Khoury P; Von Hoff D; Kraynak M; Moczygemba J; Kromelis P; Griffin T; Rowinsky E K
A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(5):605-14.
2001: Hidalgo M; Aylesworth C; Hammond L A; Britten C D; Weiss G; Stephenson J; Schwartz G; Patnaik A; Smith L; Molpus K; Felton S; Gupta E; Ferrante K J; Tortora A; Sonnichsen D S; Skillings J; Rowinsky E K
Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(9):2493-503.
2001: Forastiere A A; Leong T; Rowinsky E; Murphy B A; Vlock D R; DeConti R C; Adams G L
Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(4):1088-95.
2001: Villalona-Calero M A; Eder J P; Toppmeyer D L; Allen L F; Fram R; Velagapudi R; Myers M; Amato A; Kagen-Hallet K; Razvillas B; Kufe D W; Von Hoff D D; Rowinsky E K
Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(3):857-69.
2001: Lakhanpal S; Donehower R C; Rowinsky E K
Phase II study of 4-ipomeanol, a naturally occurring alkylating furan, in patients with advanced hepatocellular carcinoma.
Investigational new drugs 2001;19(1):69-76.
2000: Hidalgo M; Rowinsky E K
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
Oncogene 2000;19(56):6680-6.
2000: Eckhardt S G; Baker S D; Britten C D; Hidalgo M; Siu L; Hammond L A; Villalona-Calero M A; Felton S; Drengler R; Kuhn J G; Clark G M; Smith S L; MacDonald J R; Smith C; Moczygemba J; Weitman S; Von Hoff D D; Rowinsky E K
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(24):4086-97.
2000: Patnaik A; Rowinsky E K; Tammara B K; Hidalgo M; Drengler R L; Garner A M; Siu L L; Hammond L A; Felton S A; Mallikaarjun S; Von Hoff D D; Eckhardt S G
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(23):3974-85.
2000: Hammond L A; Hilsenbeck S G; Eckhardt S G; Marty J; Mangold G; MacDonald J R; Rowinsky E K; Von Hoff D D; Weitman S
Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model.
European journal of cancer (Oxford, England : 1990) 2000;36(18):2430-6.
2000: Ochoa L; Hurwitz H I; Wilding G; Cohen D; Thomas J P; Schwartz G; Monroe P; Petros W P; Ertel V P; Hsieh A; Hoffman C; Drengler R; Magnum S; Rowinsky E K
Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(10):1313-22.
2000: Britten C D; Baker S D; Denis L J; Johnson T; Drengler R; Siu L L; Duchin K; Kuhn J; Rowinsky E K
Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(9):3459-68.
2000: Rowinsky E K; Johnson T R; Geyer C E; Hammond L A; Eckhardt S G; Drengler R; Smetzer L; Coyle J; Rizzo J; Schwartz G; Tolcher A; Von Hoff D D; De Jager R L
DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(17):3151-63.
2000: Gallo J M; Laub P B; Rowinsky E K; Grochow L B; Baker S D
Population pharmacokinetic model for topotecan derived from phase I clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(12):2459-67.
2000: Tolcher A W; Aylesworth C; Rizzo J; Izbicka E; Campbell E; Kuhn J; Weiss G; Von Hoff D D; Rowinsky E K
A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(3):333-8.
2000: Baker S D; Diasio R B; O'Reilly S; Lucas V S; Khor S P; Sartorius S E; Donehower R C; Grochow L B; Spector T; Hohneker J A; Rowinsky E K
Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(4):915-26.
2000: Britten C D; Rowinsky E K; Baker S D; Weiss G R; Smith L; Stephenson J; Rothenberg M; Smetzer L; Cramer J; Collins W; Von Hoff D D; Eckhardt S G
A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(1):42-9.
2000: Rowinsky E K; Humphrey R; Hammond L A; Aylesworth C; Smetzer L; Hidalgo M; Morrow M; Smith L; Garner A; Sorensen J M; Von Hoff D D; Eckhardt S G
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(1):178-86.
2000: Hidalgo M; Villalona-Calero M A; Eckhardt S G; Drengler R L; Rodriguez G; Hammond L A; Diab S G; Weiss G; Garner A M; Campbell E; Davidson K; Louie A; O'Neil J D; von Borstel R; Von Hoff D D; Rowinsky E K
Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(1):167-77.
1999: Villalona-Calero M A; Petit T; Kuhn J; Cobb P; Kraynak M; Eckhardt S G; Drengler R; Simmons C; Santabarbara P; Von Hoff D D; Rowinsky E K
A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(11):3369-78.
1999: Rowinsky E K; Windle J J; Von Hoff D D
Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11):3631-52.
1999: Hidalgo M; Izbicka E; Eckhardt S G; MacDonald J R; Cerna C; Gomez L; Rowinsky E K; Weitman S D; Von Hoff D D
Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units.
Anti-cancer drugs 1999;10(9):837-44.
1999: Rowinsky E K
Novel radiation sensitizers targeting tissue hypoxia.
Oncology (Williston Park, N.Y.) 1999;13(10 Suppl 5):61-70.
1999: Hammond L A; Eckardt J R; Baker S D; Eckhardt S G; Dugan M; Forral K; Reidenberg P; Statkevich P; Weiss G R; Rinaldi D A; Von Hoff D D; Rowinsky E K
Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2604-13.
1999: Britten C D; Rowinsky E K; Baker S D; Agarwala S S; Eckardt J R; Barrington R; Diab S G; Hammond L A; Johnson T; Villalona-Calero M; Fraass U; Statkevich P; Von Hoff D D; Eckhardt S G
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(7):1629-37.
1999: Villalona-Calero M A; Weiss G R; Burris H A; Kraynak M; Rodrigues G; Drengler R L; Eckhardt S G; Reigner B; Moczygemba J; Burger H U; Griffin T; Von Hoff D D; Rowinsky E K
Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(6):1915-25.
1999: Eckhardt S G; Rizzo J; Sweeney K R; Cropp G; Baker S D; Kraynak M A; Kuhn J G; Villalona-Calero M A; Hammond L; Weiss G; Thurman A; Smith L; Drengler R; Eckardt J R; Moczygemba J; Hannah A L; Von Hoff D D; Rowinsky E K
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(4):1095-104.
1999: Rowinsky E K; Jiroutek M; Bonomi P; Johnson D; Baker S D
Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(4):767-74.
1999: Hidalgo M; Izbicka E; Cerna C; Gomez L; Rowinsky E K; Weitman S D; Von Hoff D D
Comparative activity of the cyclopropylpyrroloindole compounds adozelesin, bizelesin and carzelesin in a human tumor colony-forming assay.
Anti-cancer drugs 1999;10(3):295-302.
1999: Britten C D; Hilsenbeck S G; Eckhardt S G; Marty J; Mangold G; MacDonald J R; Rowinsky E K; Von Hoff D D; Weitman S
Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.
Cancer research 1999;59(5):1049-53.
1999: Petit T; Aylesworth C; Burris H; Ravdin P; Rodriguez G; Smith L; Peacock N; Smetzer L; Bellet R; Von Hoff D D; Rowinsky E K
A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(2):223-9.
1999: Baker S D; Wirth M; Statkevich P; Reidenberg P; Alton K; Sartorius S E; Dugan M; Cutler D; Batra V; Grochow L B; Donehower R C; Rowinsky E K
Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(2):309-17.
1999: Diab S G; Baker S D; Joshi A; Burris H A; Cobb P W; Villalona-Calero M A; Eckhardt S G; Weiss G R; Rodriguez G I; Drengler R; Kraynak M; Hammond L; Finizio M; Von Hoff D D; Rowinsky E K
A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(2):299-308.
1999: Britten C D; Izbicka E; Hilsenbeck S; Lawrence R; Davidson K; Cerna C; Gomez L; Rowinsky E K; Weitman S; Von Hoff D D
Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay.
Cancer chemotherapy and pharmacology 1999;44(2):105-10.
1998: Hidalgo M; Rodriguez G; Kuhn J G; Brown T; Weiss G; MacGovren J P; Von Hoff D D; Rowinsky E K
A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(11):2763-70.
1998: Gore S D; Rowinsky E K; Miller C B; Griffin C; Chen T L; Borowitz M; Donehower R C; Burks K L; Armstrong D K; Burke P J; Grever M R; Kaufmann S H
A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(11):2677-89.
1998: Rowinsky E K; Smith L; Wang Y M; Chaturvedi P; Villalona M; Campbell E; Aylesworth C; Eckhardt S G; Hammond L; Kraynak M; Drengler R; Stephenson J; Harding M W; Von Hoff D D
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(9):2964-76.
1998: Siu L L; Attardo G; Izbicka E; Lawrence R; Cerna C; Gomez L; Davidson K; Finkle C; Marsolais C; Rowinsky E K; Von Hoff D D
Activity of (-)-2'-deoxy-3'-oxacytidine (BCH-4556) against human tumor colony-forming units.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(8):885-91.
1998: Rothenberg M L; Kuhn J G; Schaaf L J; Drengler R L; Eckhardt S G; Villalona-Calero M A; Hammond L; Miller L L; Petit R G; Rowinsky E K; Von Hoff D D
Alternative dosing schedules for irinotecan.
Oncology (Williston Park, N.Y.) 1998;12(8 Suppl 6):68-71.
1998: Villalona-Calero M A; Baker S D; Hammond L; Aylesworth C; Eckhardt S G; Kraynak M; Fram R; Fischkoff S; Velagapudi R; Toppmeyer D; Razvillas B; Jakimowicz K; Von Hoff D D; Rowinsky E
Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(8):2770-9.
1998: Siu L L; Rowinsky E K
A risk-benefit assessment of irinotecan in solid tumours.
Drug safety : an international journal of medical toxicology and drug experience 1998;18(6):395-417.
1998: Hammond L A; Eckardt J R; Ganapathi R; Burris H A; Rodriguez G A; Eckhardt S G; Rothenberg M L; Weiss G R; Kuhn J G; Hodges S; Von Hoff D D; Rowinsky E K
A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(6):1459-67.
1998: Eckhardt S G; Baker S D; Eckardt J R; Burke T G; Warner D L; Kuhn J G; Rodriguez G; Fields S; Thurman A; Smith L; Rothenberg M L; White L; Wissel P; Kunka R; DePee S; Littlefield D; Burris H A; Von Hoff D D; Rowinsky E K
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(3):595-604.
1998: Rodriguez G I; Kuhn J G; Weiss G R; Hilsenbeck S G; Eckardt J R; Thurman A; Rinaldi D A; Hodges S; Von Hoff D D; Rowinsky E K
A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea.
Blood 1998;91(5):1533-41.
1998: Rowinsky E K; Baker S D; Burks K; O'Reilly S; Donehower R C; Grochow L B
High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(2):173-80.
1998: Kennedy M J; Zahurak M L; Donehower R C; Noe D; Grochow L B; Sartorius S; Chen T L; Bowling K; Duerr M; Rowinsky E K
Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doublet.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(2):349-56.
1998: O'Reilly S; Baker S D; Sartorius S; Rowinsky E K; Finizio M; Lubiniecki G M; Grochow L B; Gray J E; Pieniaszek H J; Donehower R C
A phase I and pharmacologic study of DMP 840 administered by 24-hour infusion.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(1):101-4.
1998: Siu L L; Von Hoff D D; Rephaeli A; Izbicka E; Cerna C; Gomez L; Rowinsky E K; Eckhardt S G
Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units.
Investigational new drugs 1998;16(2):113-9.
1997: Rowinsky E K; Kaufmann S H
Topotecan in combination chemotherapy.
Seminars in oncology 1997;24(6 Suppl 20):S20-11-S20-26.
1997: Rowinsky E K; Verweij J
Review of phase I clinical studies with topotecan.
Seminars in oncology 1997;24(6 Suppl 20):S20-3-S20-10.
1997: Rowinsky E; Smith L; Rodriguez G; White L; Drengler R; Von Hoff D; Peacock N; Aylesworth C; Burris H; Ravdin P; Bellet R
Docetaxel in combination with fluorouracil: study design and preliminary results.
Oncology (Williston Park, N.Y.) 1997;11(6 Suppl 6):33-5.
1997: Adjei A A; Budihardjo I I; Rowinsky E K; Kottke T J; Svingen P A; Buckwalter C A; Grochow L B; Donehower R C; Kaufmann S H
Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(5):761-70.
1997: O'Reilly S; Grochow L B; Donehower R C; Chen T L; Bowling K; Hartman N R; Struck R F; Rowinsky E K
Phase I and pharmacologic study of penclomedine, a novel alkylating agent, in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):1974-84.
1997: Rowinsky E K; Long G S; Noe D A; Grochow L B; Bowling M K; Sartorius S E; Donehower R C
Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(3):401-7.
1997: Rowinsky E K
The taxanes: dosing and scheduling considerations.
Oncology (Williston Park, N.Y.) 1997;11(3 Suppl 2):7-19.
1997: O'Reilly S; Fleming G F; Barker S D; Walczak J R; Bookman M A; McGuire W P; Schilder R J; Alvarez R D; Armstrong D K; Horowitz I R; Ozols R F; Rowinsky E K
Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):177-86.
1997: Rowinsky E K; Flood W A; Sartorius S E; Bowling K M; Ettinger D S
Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer.
Investigational new drugs 1997;15(2):129-38.
1997: Rowinsky E K
The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents.
Annual review of medicine 1997;48():353-74.
1996: Rowinsky E K; Kaufmann S H; Baker S D; Miller C B; Sartorius S E; Bowling M K; Chen T L; Donehower R C; Gore S D
A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(12):1921-30.
1996: Kaufmann S H; Gore S D; Letendre L; Svingen P A; Kottke T; Buckwalter C A; Jones R J; Grochow L B; Burke P J; Donehower R C; Rowinsky E K
Factors affecting topotecan sensitivity in human leukemia samples.
Annals of the New York Academy of Sciences 1996;803():128-42.
1996: Baker S D; Khor S P; Adjei A A; Doucette M; Spector T; Donehower R C; Grochow L B; Sartorius S E; Noe D A; Hohneker J A; Rowinsky E K
Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(12):3085-96.
1996: Rowinsky E K; Kaufmann S H; Baker S D; Grochow L B; Chen T L; Peereboom D; Bowling M K; Sartorius S E; Ettinger D S; Forastiere A A; Donehower R C
Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(12):3074-84.
1996: O'Reilly S; Rowinsky E K; Slichenmyer W; Donehower R C; Forastiere A A; Ettinger D S; Chen T L; Sartorius S; Grochow L B
Phase I and pharmacologic study of topotecan in patients with impaired renal function.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(12):3062-73.
1996: Hartman N R; O'Reilly S; Rowinsky E K; Collins J M; Strong J M
Murine and human in vivo penclomedine metabolism.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(6):953-62.
1996: O'Reilly S; Donehower R C; Rowinsky E K; Ord S; Grochow L B
A phase II trial of topotecan in patients with previously untreated pancreatic cancer.
Anti-cancer drugs 1996;7(4):410-4.
1996: O'Reilly S; Rowinsky E; Slichenmyer W; Donehower R C; Forastiere A; Ettinger D; Chen T L; Sartorius S; Bowling K; Smith J; Brubaker A; Lubejko B; Ignacio V; Grochow L B
Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function.
Journal of the National Cancer Institute 1996;88(12):817-24.
1996: Kaufmann S H; Peereboom D; Buckwalter C A; Svingen P A; Grochow L B; Donehower R C; Rowinsky E K
Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines.
Journal of the National Cancer Institute 1996;88(11):734-41.
1996: Rowinsky E K; Grochow L B; Sartorius S E; Bowling M K; Kaufmann S H; Peereboom D; Donehower R C
Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(4):1224-35.
1996: O'Reilly S; Hartman N R; Grossman S A; Strong J M; Struck R F; Eller S; Lesser G J; Donehower R C; Rowinsky E K
Tissue and tumor distribution of C-penclomedine in rats.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(3):541-8.
1996: Kennedy M J; Zahurak M L; Donehower R C; Noe D A; Sartorius S; Chen T L; Bowling K; Rowinsky E K
Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(3):783-91.
1996: Rowinsky E K; Lucas V S; Hsieh A L; Wargin W A; Hohneker J A; Lubejko B; Sartorius S E; Donehower R C
The effects of food and divided dosing on the bioavailability of oral vinorelbine.
Cancer chemotherapy and pharmacology 1996;39(1-2):9-16.
1995: Rowinsky E K; Flood W A; Sartorius S E; Bowling M K; Wagner J; Ettinger D S
Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer.
Seminars in oncology 1995;22(4 Suppl 9):48-54.
1995: Rowinsky E K; Noe D A; Grochow L B; Sartorious S E; Bowling M K; Chen T L; Lubejko B G; Kaufmann S H; Donehower R C
Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(8):1975-84.
1995: Kennedy M J; Donehower R C; Rowinsky E K
Treatment of metastatic breast cancer with combination paclitaxel/cyclophosphamide.
Seminars in oncology 1995;22(4 Suppl 8):23-7.
1995: Rowinsky E K
The suitability of selected new anticancer agents for infusional therapy and the effects of others on infusional therapy practices.
The Journal of infusional chemotherapy 1995;5(4):173-8.
1995: Slichenmyer W J; Donehower R C; Chen T L; Bowling M K; McGuire W P; Rowinsky E K
Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia.
Cancer chemotherapy and pharmacology 1995;36(3):227-32.
1995: O'Reilly S; Kennedy M J; Rowinsky E K; Donehower R C
Vinorelbine and the topoisomerase 1 inhibitors: current and potential roles in breast cancer chemotherapy.
Breast cancer research and treatment 1995;33(1):1-17.
1995: Lesser G J; Grossman S A; Eller S; Rowinsky E K
The distribution of systemically administered [3H]-paclitaxel in rats: a quantitative autoradiographic study.
Cancer chemotherapy and pharmacology 1995;37(1-2):173-8.
1994: Rowinsky E K; Adjei A; Donehower R C; Gore S D; Jones R J; Burke P J; Cheng Y C; Grochow L B; Kaufmann S H
Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(10):2193-203.
1994: Rowinsky E K; Noe D A; Trump D L; Winer E P; Lucas V S; Wargin W A; Hohneker J A; Lubejko B; Sartorius S E; Ettinger D S
Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(9):1754-63.
1994: Rowinsky E K
Update on the antitumor activity of paclitaxel in clinical trials.
The Annals of pharmacotherapy 1994;28(5 Suppl):S18-22.
1994: Chaudhry V; Rowinsky E K; Sartorius S E; Donehower R C; Cornblath D R
Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies.
Annals of neurology 1994;35(3):304-11.
1994: Rowinsky E K; Grochow L B; Ettinger D S; Sartorius S E; Lubejko B G; Chen T L; Rock M K; Donehower R C
Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
Cancer research 1994;54(2):427-36.
1994: Rowinsky E K; Wright M; Monsarrat B; Donehower R C
Clinical pharmacology and metabolism of Taxol (paclitaxel): update 1993.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5 Suppl 6():S7-16.
1994: Slichenmyer W J; Rowinsky E K; Grochow L B; Kaufmann S H; Donehower R C
Camptothecin analogues: studies from the Johns Hopkins Oncology Center.
Cancer chemotherapy and pharmacology 1994;34 Suppl():S53-7.
1993: Rowinsky E K; Chaudhry V; Forastiere A A; Sartorius S E; Ettinger D S; Grochow L B; Lubejko B G; Cornblath D R; Donehower R C
Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(10):2010-20.
1993: Rowinsky E K; Donehower R C
The clinical pharmacology of paclitaxel (Taxol).
Seminars in oncology 1993;20(4 Suppl 3):16-25.
1993: Rowinsky E K; Eisenhauer E A; Chaudhry V; Arbuck S G; Donehower R C
Clinical toxicities encountered with paclitaxel (Taxol).
Seminars in oncology 1993;20(4 Suppl 3):1-15.
1993: Peereboom D M; Donehower R C; Eisenhauer E A; McGuire W P; Onetto N; Hubbard J L; Piccart M; Gianni L; Rowinsky E K
Successful re-treatment with taxol after major hypersensitivity reactions.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(5):885-90.
1993: Rowinsky E K; Noe D A; Ettinger D S; Christian M C; Lubejko B G; Fishman E K; Sartorius S E; Boyd M R; Donehower R C
Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans.
Cancer research 1993;53(8):1794-801.
1993: Slichenmyer W J; Rowinsky E K; Donehower R C; Kaufmann S H
The current status of camptothecin analogues as antitumor agents.
Journal of the National Cancer Institute 1993;85(4):271-91.
1993: Rowinsky E K; Citardi M J; Noe D A; Donehower R C
Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine.
Journal of cancer research and clinical oncology 1993;119(12):727-33.
1992: Rowinsky E K; Onetto N; Canetta R M; Arbuck S G
Taxol: the first of the taxanes, an important new class of antitumor agents.
Seminars in oncology 1992;19(6):646-62.
1992: Grochow L B; Rowinsky E K; Johnson R; Ludeman S; Kaufmann S H; McCabe F L; Smith B R; Hurowitz L; DeLisa A; Donehower R C
Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer.
Drug metabolism and disposition: the biological fate of chemicals 1992;20(5):706-13.
1992: Rowinsky E K; Conley B A; Jones R J; Spivak J L; Auerbach M; Donehower R C
Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrations.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6(6):526-34.
1992: Hendricks C B; Rowinsky E K; Grochow L B; Donehower R C; Kaufmann S H
Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.
Cancer research 1992;52(8):2268-78.
1992: Rowinsky E K; Grochow L B; Hendricks C B; Ettinger D S; Forastiere A A; Hurowitz L A; McGuire W P; Sartorius S E; Lubejko B G; Kaufmann S H
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(4):647-56.
1991: Hendricks C B; Grochow L B; Rowinsky E K; Forastiere A A; McGuire W P; Ettinger D S; Sartorius S; Lubejko B; Donehower R C
Phase I and pharmacokinetic study of hepsulfam (NSC 329680).
Cancer research 1991;51(21):5781-5.
1991: Rowinsky E K; McGuire W P; Guarnieri T; Fisherman J S; Christian M C; Donehower R C
Cardiac disturbances during the administration of taxol.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(9):1704-12.
1991: Rowinsky E K; Gilbert M R; McGuire W P; Noe D A; Grochow L B; Forastiere A A; Ettinger D S; Lubejko B G; Clark B; Sartorius S E
Sequences of taxol and cisplatin: a phase I and pharmacologic study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(9):1692-703.
1991: McGuire W P; Rowinsky E K
Old drugs revisited, new drugs, and experimental approaches in ovarian cancer therapy.
Seminars in oncology 1991;18(3):255-69.
1990: Rowinsky E K; Donehower R C; Spivak J L; Burke P J; Griffin C A; Jones R J
Effects of the differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic progenitors.
Journal of the National Cancer Institute 1990;82(24):1926-31.
1990: Noe D A; Rowinsky E K; Shen H S; Clarke B V; Grochow L B; McGuire W B; Hantel A; Adams D B; Abeloff M D; Ettinger D S
Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).
Cancer research 1990;50(15):4595-9.
1990: Rowinsky E K; Cazenave L A; Donehower R C
Taxol: a novel investigational antimicrotubule agent.
Journal of the National Cancer Institute 1990;82(15):1247-59.
1990: Hantel A; Donehower R C; Rowinsky E K; Vance E; Clarke B V; McGuire W P; Ettinger D S; Noe D A; Grochow L B
Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole.
Cancer research 1990;50(11):3284-8.
1990: Jones R J; Sharkis S J; Miller C B; Rowinsky E K; Burke P J; May W S
Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitro.
Blood 1990;75(6):1319-23.
1989: Rowinsky E K; Grochow L B; Hantel A; Ettinger D S; Vito B L; Donehower R C
Assessment of N-methylformamide (NMF) administered orally on a three times weekly schedule: a phase I study.
Investigational new drugs 1989;7(4):317-25.
1989: McGuire W P; Rowinsky E K; Rosenshein N B; Grumbine F C; Ettinger D S; Armstrong D K; Donehower R C
Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.
Annals of internal medicine 1989;111(4):273-9.
1989: Rowinsky E K; Burke P J; Karp J E; Tucker R W; Ettinger D S; Donehower R C
Phase I and pharmacodynamic study of taxol in refractory acute leukemias.
Cancer research 1989;49(16):4640-7.
1989: Grochow L B; Noe D A; Dole G B; Rowinsky E K; Ettinger D S; Graham M L; McGuire W P; Donehower R C
Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamics.
Journal of the National Cancer Institute 1989;81(2):124-30.
1988: Hantel A; Rowinsky E K; Noe D A; McGuire W P; Grochow L B; Vito B L; Ettinger D S; Donehower R C
Clinical and pharmacologic reappraisal of dichloromethotrexate.
Journal of the National Cancer Institute 1988;80(19):1547-53.
1988: Rowinsky E K; Noe D A; Orr D W; Grochow L B; Ettinger D S; Donehower R C
Clinical pharmacology of oral and i.v. N-methylformamide: a pharmacologic basis for lack of clinical antineoplastic activity.
Journal of the National Cancer Institute 1988;80(9):671-8.
1988: Rowinsky E K; Donehower R C; Jones R J; Tucker R W
Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol.
Cancer research 1988;48(14):4093-100.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Eric Rowinsky

Research Profile (preview)

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Eric Rowinsky (preview)

All Publications